Company intelligence / Profile preview

Galaxy Biotech

Sunnyvale, California, United Statesgalaxybiotech.co.in ↗

Ownership: Private
Development stage: Other

Overview

Galaxy Biotech has developed humanized monoclonal antibodies targeting growth factors and their receptors for oncology indications. Its lead asset, HuL2G7—an anti-HGF antibody—completed a Phase I trial with Takeda/Millennium showing an excellent safety profile. The company is seeking to outlicense this asset for further development.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyHumanized antibodyAntibody (general)
Industry: Biotech

Drug pipeline

2 assets

L2G7

Preclinical

1 more asset in the full pipeline.

Partnerships

Takeda Pharmaceutical Company / Millennium Pharmaceuticals (previous licensee of anti-HGF program)Geller Biopharm (engaged as exclusive agent for licensing/outlicensing support)

Beyond the preview

Go deeper on Galaxy Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galaxy Biotech.